CALI BIOTPAR |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.75 USD | +10.55% |
|
+7.96% | -88.41% |
| 07-08 | Calidi Biotherapeutics, Inc. Enters into A Certain Loan Agreement with Dennis R. Conklin | CI |
| 07-05 | Calidi Biotherapeutics to Implement 1-For-10 Reverse Stock Split | MT |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 11.23M 867M |
|---|---|---|---|---|---|
| Net income 2024 * | -32M -2.47B | Net income 2025 * | -36M -2.78B | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-0.35
x | P/E ratio 2025 * |
-0.97
x | Employees | 41 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 6.03% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +10.55% | ||
| 1 week | +7.96% | ||
| Current month | -12.50% | ||
| 1 month | -14.22% | ||
| 3 months | -70.83% | ||
| 6 months | -86.43% | ||
| Current year | -88.41% |
1 week
1.44
2.18
1 month
1.412.20
Current year
1.4116.80
1 year
1.41137.90
3 years
1.41137.90
5 years
1.41137.90
10 years
1.41137.90
| Managers | Title | Age | Since |
|---|---|---|---|
Allan Camaisa
CEO | Chief Executive Officer | - | - |
Andrew Jackson
DFI | Director of Finance/CFO | 55 | 29/10/23 |
Amish A. Patel
CTO | Chief Tech/Sci/R&D Officer | 47 | 31/07/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
George Ng
BRD | Director/Board Member | 49 | 30/09/19 |
Alan Stewart
BRD | Director/Board Member | 60 | 09/10/23 |
James Schoeneck
BRD | Director/Board Member | 66 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/07/24 | 1.75 | +10.55% | 453,499 |
| 12/07/24 | 1.583 | +4.42% | 152,094 |
| 11/07/24 | 1.516 | 0.00% | 144,139 |
| 10/07/24 | 1.516 | +0.73% | 76,188 |
| 09/07/24 | 1.505 | -7.16% | 251,796 |
Delayed Quote Nyse, July 15, 2024 at 09:10 pm
More quotes
Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's novel stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Its clinical-stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses. Its preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach shall potentially treat, or even prevent, metastatic disease. Its product candidates include CLD-101 for Recurrent HGG; CLD-201 for Advanced Solid Tumors, and CLD-400 (RTNova) for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline product candidates, the Company's is also engaged in discovery research of CLD-301 (AAA) for multiple Indications.
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.75
USD
Average target price
15
USD
Spread / Average Target
+757.14%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -88.41% | 11.23M | |
| +20.63% | 127B | |
| +25.01% | 27.67B | |
| -20.17% | 20.33B | |
| -17.17% | 16.79B | |
| -18.07% | 15.63B | |
| -47.70% | 14.65B | |
| +11.92% | 14.84B | |
| +58.32% | 14.43B | |
| +149.98% | 12.49B |
- Stock Market
- Equities
- CLDI Stock
